Jul. 6 at 4:02 PM
$DTIL BooooomBittyBooom! Don't forget "iEcure" future revs...
iECURE Three benefits drive value
- Pipeline
$288 Million Potential
- Milestone Payouts:
- DTIL eligible up to $ 288M future clinical, regulatory, & commercial milestone payments.
- Payout spans four rare genetic disease programs by iECURE
- They're using PB’s PCSK9-directed ARCUS nuclease platform.
- As iECURE advances Phase 1/2 OTC-HOPE trial for ECUR-506 across Australia, U.S., & U.K., clinical progression triggers milestones.
Global royalty commercial payout:
- If iECURE succeed DTIL collects high-single-digit to low-double-digit royalties on net sales worldwide.
- Passive revenue: high-margin, long-term
- Boost DTIL future earnings potential
Equity Ownership stake:
- Instead of upfront cash fee, DTIL secured equity stake in iECURE at deal closure.
